Silver Book Fact

Treatment with zoledronic acid over a 3-year period reduced risk of vertebral fracture by around 70% and risk of hip fracture by 41%, and increased bone mineral density (BMD) by 5% to 6%.

Black, Dennis M. et al. Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. NEJM. 2007; 356(18): 1809-22. http://content.nejm.org/cgi/content/abstract/356/18/1809

Reference

Title
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Publication
NEJM
Publication Date
2007
Authors
Black, Dennis M. et al.
Volume & Issue
Volume 356, Issue 18
Pages
1809-22
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • A recent study found that more postmenopausal women who took the drug denosumab gained at least 3% of bone mass at the hip and spine than those who took…  
  • Alendronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by as much as 8% over 3-years in postmenopausal women with osteoporosis.  
  • Ibandronate, a bisphosphonate, taken daily has been shown to reduce the risk of new vertebral fractures by around 62%.  
  • Patients with vertebral fractures who underwent kyphoplasty, a procedure that stabilizes fractures of the spine, were found in one study to have reduced pain, fewer new fractures, and less healthcare…  
  • Hip fracture prevention in at-risk, postmenopausal women saves $333 million annually.